
News|Articles|October 21, 2025
Executive Summary: Mastering Nitrosamines Analysis With Streamlined LC-MS/MS Solutions
Author(s)SCIEX
Nitrosamine contamination in pharmaceuticals has become a major regulatory concern due to their potent carcinogenicity, requiring ultra-trace-level detection to ensure patient safety. Advanced LC-MS/MS workflows provide the necessary sensitivity, selectivity, and robustness to accurately quantify nitrosamine drug substance-related impurities (NDSRIs), even within complex pharmaceutical matrices. Case studies with betahistine, orphenadrine, and chloropyramine demonstrate how streamlined LC-MS/MS strategies can reliably detect and confirm nitrosamine impurities well below regulatory thresholds.
Trending on LCGC International
1
Chromatographic and Mass Spectrometric Screening of Novel Psychoactive Substances in Seized Drug Analysis
2
Industry Roundup: Thermo Fisher Scales Orbitrap Platform Across Research, Biopharma, and Environmental Testing at ASMS 2026
3
Industry Roundup: Bruker Unveils Next-Generation Multiomics MS Tools at ASMS
4
Analytical Solutions for PFAS Testing - Routine to Discovery Analysis in Environmental Samples and Consumer Products
5
